Industry News
-
Ocugen Completes Phase 3 Enrollment for OCU400 Gene-Agnostic AAV Therapy in Retinitis Pigmentosa
Mar 02 2026 -
Opus Genetics Reports Early Phase I/II Data for OPGx-BEST1 AAV Gene Therapy in BEST1 Retinal Diseases
Mar 02 2026 -
FDA Reaffirms Requirement for New Trial of uniQure’s AAV5 Gene Therapy AMT-130
Mar 02 2026 -
A2 Bio Advances Logic-Gated CAR-T Therapy A2B543 in EVEREST-2 Trial for Solid Tumors
Mar 02 2026 -
Gemma Biotherapeutics Doses First Patient in AAV Gene Therapy Trial for SMA1
Feb 26 2026 -
Neurogene’s AAV9 Gene Therapy NGN-401 Earns FDA Breakthrough Therapy Designation for Rett Syndrome
Feb 26 2026 -
Pfizer Exercises Option for Beam’s Liver-Targeted Base Editing Program
Feb 25 2026 -
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 AAV Immuno-Gene Therapy in Recurrent High-Grade Glioma
Feb 24 2026 -
FDA Accepts BLA for Ultragenyx’s DTX401 AAV8 Gene Therapy in GSDIa
Feb 23 2026